Department of Gastroenterology and Hepatology, Amsterdam UMC, location VU Medical Center, AGEM Research Institute, Amsterdam, the Netherlands; Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands.
Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands.
Curr Opin Pharmacol. 2022 Oct;66:102268. doi: 10.1016/j.coph.2022.102268. Epub 2022 Jul 31.
Celiac Disease (CeD) is a chronic intestinal disease which occurs in 0.7-1.4% of the global population. Since the discovery of gluten as its disease-inducing antigen, CeD patients are treated with a gluten-free diet which is effective but has limitations for certain groups of patients. Accordingly, over the past few years, there is a growing interest in alternative treatment options. This review summarizes emerging pharmacological approaches, including tolerance induction strategies, tissue transglutaminase inhibition, gluten degradation, and inhibition of interleukin (IL)-15.
乳糜泻(CeD)是一种慢性肠道疾病,全球人群发病率为 0.7-1.4%。自从发现麸质是其致病抗原以来,乳糜泻患者一直采用无麸质饮食进行治疗,这种方法虽然有效,但对某些患者群体存在局限性。因此,在过去几年中,人们对替代治疗方案产生了浓厚的兴趣。本综述总结了新兴的药理学方法,包括诱导耐受策略、组织转谷氨酰胺酶抑制、 gluten 降解和抑制白细胞介素(IL)-15。